Stem Cell Therapeutics Corp. Announces That Dr. Alan Moore Will Present a Novel, Drug-Based Approach to Neuron Regeneration at t
23 September 2009 - 10:30PM
Marketwired
Stem Cell Therapeutics Corp. ("SCT") (TSX VENTURE: SSS) announced
that Dr. Alan Moore, President and CEO, will be featured in today's
panel discussion "Commercialization of Stem Cells and International
Market Trends" at the 2009 World Stem Cell Summit being held in
Baltimore, Maryland, September 21-23.
Dr. Alan Moore, President and CEO of SCT, commented as
follows:
"I am pleased to be a part of this 'state of the industry'
discussion with fellow regenerative medicine and stem cell business
leaders. This is an exciting and interesting time for stem cell
related therapies and I feel our drug-based treatment offers a
unique alternative to stem cell based therapies for regenerative
medicine."
About the World Stem Cell Summit
(http://www.worldstemcellsummit.com/): The World Stem Cell Summit
unites the stem cell universe of researchers, ReGEN industry
leaders, funders, medical philanthropies, policy-makers, advocates,
educators and regulators to chart the future of regenerative
medicine. The comprehensive, multi-track program covers advanced
science, commercial perspectives, disease progress reports and
in-depth reviews of policy, law, ethics, regulatory issues and
global economic development. The 2009 Summit will feature 125
presenting experts, attendees from 25 countries and representatives
from more 200 sponsors, supporting organizations and media
partners, at the preeminent international networking event.
About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp.
is a public biotechnology company (TSX-V: SSS) focused on the
development and commercialization of drug-based therapies to treat
central nervous system diseases. SCT is a leader in the development
of therapies that utilize drugs to stimulate a patient's own
resident stem cells. The Company's programs aim to repair brain and
nerve function lost due to disease or injury. The Company's
extensive patent portfolio of owned and licensed intellectual
property supports the potential expansion into future clinical
programs in numerous neurological diseases such as traumatic brain
injury, multiple sclerosis, Huntington's disease, Alzheimer's
disease, and ALS.
These securities have not been registered under the United
States Securities Act of 1933, as amended, or the securities laws
of any state, and may not be offered or sold within the United
States or to, or for the account or benefit of U.S. persons unless
an applicable exemption from U.S. registration requirements is
available.
Except for historical information, this press release may
contain forward-looking statements, which reflect the Company's
current expectation regarding future events. These forward-looking
statements involve risk and uncertainties, which may cause but are
not limited to, changing market conditions, the successful and
timely completion of clinical studies, the establishment of
corporate alliances, the impact of competitive products and
pricing, new product development, uncertainties related to the
regulatory approval process and other risks detailed from time to
time in the Company's ongoing quarterly and annual reporting.
The TSX Venture Exchange does not accept responsibility for the
adequacy or accuracy of this release.
Contacts: Stem Cell Therapeutics Corp. Alan Moore, PhD President
and CEO (403) 245-5495 ext.224 amoore@stemcellthera.com Stem Cell
Therapeutics Corp. Chloe Douglas-Crampton Investor Relations (403)
245-5495 ext. 221 crampton@stemcellthera.com
www.stemcellthera.com
Sunvest Minerals Corp (TSXV:SSS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Sunvest Minerals Corp (TSXV:SSS)
Historical Stock Chart
From Jul 2023 to Jul 2024